Literature DB >> 21644031

Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.

Beatriz Sanchez-Correa1, Sara Morgado, Inmaculada Gayoso, Juan M Bergua, Javier G Casado, Maria Jose Arcos, Maria Luisa Bengochea, Esther Duran, Rafael Solana, Raquel Tarazona.   

Abstract

Natural killer (NK) cell activation is strictly regulated to ensure that healthy cells are preserved, but tumour-transformed or virus-infected cells are recognized and eliminated. To carry out this selective killing, NK cells have an ample repertoire of receptors on their surface. Signalling by inhibitory and activating receptors by interaction with their ligands will determine whether the NK cell becomes activated and kills the target cell. Here, we show reduced expression of NKp46, NKp30, DNAM-1, CD244 and CD94/NKG2C activating receptors on NK cells from acute myeloid leukaemia patients. This reduction may be induced by chronic exposure to their ligands on leukaemic blasts. The analysis of ligands for NK cell-activating receptors showed that leukaemic blasts from the majority of patients express ligands for NK cell-activating receptors. DNAM-1 ligands are frequently expressed on blasts, whereas the expression of the NKG2D ligand MICA/B is found in half of the patients and CD48, a ligand for CD244, in only one-fourth of the patients. The decreased expression of NK cell-activating receptors and/or the heterogeneous expression of ligands for major receptors on leukaemic blasts can lead to an inadequate tumour immunosurveillance by NK cells. A better knowledge of the activating receptor repertoire on NK cells and their putative ligands on blasts together with the possibility to modulate their expression will open new possibilities for the use of NK cells in immunotherapy against leukaemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21644031     DOI: 10.1007/s00262-011-1050-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors:  Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cancer Immunol Res       Date:  2018-11-05       Impact factor: 11.151

3.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

4.  Anticancer activity of emodin is associated with downregulation of CD155.

Authors:  Liang Fang; Fang Zhao; Stephen Iwanowycz; Junfeng Wang; Sophia Yin; Yuzhen Wang; Daping Fan
Journal:  Int Immunopharmacol       Date:  2019-07-17       Impact factor: 4.932

5.  VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.

Authors:  Xueyan Ren; Wei Xie; Youfu Wang; Menghuai Xu; Fang Liu; Mingying Tang; Chenchen Li; Min Wang; Juan Zhang
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

Review 6.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 7.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

8.  Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.

Authors:  Julia D Suerth; Michael A Morgan; Stephan Kloess; Dirk Heckl; Christine Neudörfl; Christine S Falk; Ulrike Koehl; Axel Schambach
Journal:  J Mol Med (Berl)       Date:  2015-08-25       Impact factor: 4.599

9.  KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.

Authors:  Meixin Shen; Yeh-Ching Linn; Ee-Chee Ren
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

Review 10.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.